Exploiting Lactoferricin (17–30) as a Potential Antimicrobial and Antibiofilm Candidate Against Multi-Drug-Resistant Enteroaggregative Escherichia coli

Vergis, Jess; Malik, S.V.S.; Pathak, Richa; Kumar, Manesh; Ramanjaneya, Sunitha; Kurkure, N. V.; Barbuddhe, Sukhadeo B.; Rawool, Deepak B.

doi:10.3389/fmicb.2020.575917

Cited by 9 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Morroni G et al found that the antimicrobial peptide LL-37 has good antibacterial activity against multidrug-resistant E. coli, and MIC and sub-MIC concentrations of LL-37 were able to reduce E. coli bio lm formation [21]. Vergis J et al found that the antimicrobial peptide lactoferricin (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) has good antibacterial and antibio lm activity against multidrug-resistant enteroaggregative E. coli, and lactoferricin (17-30) signi cantly reduced the formation of E. coli bio lms [22]. Mishra BE et al found that the antimicrobial peptide WW298 could effectively inhibit MRSA attachment and disrupt its preformed bio lms more effectively than daptomycin [23].…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial peptide Mastoparan X has good activity against Escherichia coli in vitro and alleviates its pathogenicity in mice

Zhao

Wang

Zhu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Escherichia coli is a facultative anaerobic bacterium that exists in the gastrointestinal tract of humans and animals and can cause diarrhoea and enteritis. The antimicrobial peptide MPX is extracted from wasp venom and has a strong bactericidal effect on many bacteria. The aim of this study was to explore the mechanism by whichMPX kills E. coli in vitro, its effect on IPEC-J2 cells apoptosis and barrier function, and itstherapeutic effect on E. coli infection in mice. Methods: In this study, the effects of MPX on E. coli were investigated in vitro, at cellular level and in vivo. Results: The results showedthat the minimum inhibitory concentration (MIC) of MPX against E. coli was 31.25 µg/mL. Scanning electron microscopy results showed that the bacteria became smaller in size and the contents leaked after treatment with MPX. In addition, theNPN, PI and DiSC3(5) results showed that the fluorescence intensity was positively correlated with MPX. MPX significantly inhibited E. coli biofilm formation. Moreover, MPX effectively alleviated IPEC-J2 cell apoptosis, regulated ZO-1, Occludin, and Claudin-1 through theRac1 pathway. H&E staining results further found that MPX could alleviate the pathological damage in intestine. qRT–PCR results showed that MPX could increase the mRNA expression of TFF3 in the jejunum and colon. Conclusions: This study is the first time to explore the mechanism by which MPX kills E. coli in vitro, laying the foundation for the development of new drugs for the treatment of bacterial infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Antimicrobial peptide Mastoparan X has good activity against Escherichia coli in vitro and alleviates its pathogenicity in mice

Zhao

Wang

Zhu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The formation of bacteria biofilm leads to an increase in bacterial resistance. Morroni G et al found that the antimicrobial peptide LL-37 has good antibacterial activity against multi-drug resistant E. coli, and MIC and sub-MIC concentrations of LL-37 were able to reduce E. coli biofilm formation (Morroni G. et al, 2021) Vergis J et al found that the antimicrobial peptide Lactoferricin (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) has good antibacterial and anti-biofilm activity against multi-drug-resistant Enteroaggregative Escherichia coli, and Lactoferricin (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) significantly reduced the formation of E. coli biofilm (Vergis J. et al, 2020) Mishra BE et al found that antimicrobial peptide WW298 could effectively inhibit the MRSA attachment and disrupt its preformed biofilms more effectively than daptomycin (Mishra B. et al, 2020). Liu Ye et al found that tryptophan-rich amphiphilic peptide termed WRK-12 significantly inhibited the formation of biofilm in a dose-dependent manner, especially multidrug-resistant (MDR) bacteria particularly Gramnegative bacteria (Liu Y. et al, 2020) This study found that MPX (1 MIC) significantly inhibited the formation of E. coli biofilm, indicating that antibacterial peptides have a good antibacterial biofilm formation effect, which lays the foundation for the development of antibacterial biofilm formation drugs.…”

Section: Discussionmentioning

confidence: 99%

The Mechanism of Antimicrobial Peptide MPX against Enterohemorrhagic Escherichia coli in Vitro

Дзяо¹,

Фотіна²,

Ванг³

et al. 2021

View full text Add to dashboard Cite

Escherichia coli is a facultative anaerobic bacteria that exists in the gastrointestinal tract of humans and animals. It can cause diarrhea, enteritis, destruction of the host's intestinal barrier, and intestinal microecological disturbances. In recent years, due to the abuse of traditional antibiotics, a variety of drug-resistant strains and super bacteria have emerged in an endless stream. Therefore, there is an urgent need to find new alternatives to antibiotics. Antimicrobial peptides are a type of small peptides produced when organisms resist the invasion of foreign microorganisms. They are considered to be the best alternative to antibiotics which has become a research hotspot in recent years. The antimicrobial peptide MPX is extracted from wasp venom and has a good bactericidal effect on many bacteria. To explore the effect of MPX against E. coli. The function of MPX against E. coli was detected by MIC, plate count, propidium iodide, NPN and DiSC3(5) permeability testing, immunofluorescence microscope observation, and the impact of MPX stability by temperature, pH, ion. In this study, the results found that MPX has good antibacterial activity against E. coli, and the minimum inhibitory concentration (MIC) was 31.25 ug/mL. MPX bactericidal kinetics study found that MPX had good bactericidal activity within 6 hours. Bacterial permeability studies have shown that MPX could increase the permeability of bacteria, leading to an increase in the protein content of the bacterial supernatant. In addition, NPN, PI and DiSC3(5) results showed that the fluorescence value was positively correlated with MPX. The stability test of MPX found that salt ions, temperature, pH, etc. have a slight influence on its effect. In addition, scanning electron microscopy results showed that the bacteria became smaller and the contents leaked after the action of MPX. The above results showed that MPX has a good bactericidal activity in vitro, laying the foundation for the development of new drugs for the treatment of bacterial infections.

show abstract

“…Hence, recent studies are focused on exploring alternative antimicrobial therapeutics; most importantly, phytochemicals, bacteriophages, probiotics, endolysins and antimicrobial peptides (AMPs) as effective alternative treatment methods for such infections (Thombre et al ., 2019). Of late, AMPs are regarded as viable alternatives to existing antibiotics (Dutta, 2020), due to their potential antimicrobial, antifouling, as well as immunomodulatory properties, and could seldom acquire resistance (Vergis et al ., 2020). Nevertheless, the efficacy of cationic AMPs in clearing intracellular infections, especially NTS strains, remains deficient (Gourkhede et al ., 2020).…”

Section: Introductionmentioning

confidence: 99%

Antibacterial efficacy of in‐house designed cell‐penetrating peptide against multi‐drug resistant strains of Salmonella Enteritidis and Salmonella Typhimurium

Nishanth

Bhoomika

Gourkhede

et al. 2021

Environmental Microbiology

Self Cite

View full text Add to dashboard Cite

Summary The in vitro antibacterial efficacy of an in‐house designed cell‐penetrating peptide (CPP) variant of Cecropin A (1–7)‐Melittin (CAMA) (CAMA‐CPP) against the characterized multi‐drug resistant (MDR) field strains of Salmonella Enteritidis and Salmonella Typhimurium were evaluated and compared with two identified CPPs namely, P7 and APP, keeping CAMA as control. Initially, the minimum inhibitory concentration (MIC) (μg ml−1) of in‐house designed CAMA‐CPP, APP and CAMA was determined to be 3.91, whereas that of P7 was 7.81; however, the minimum bactericidal concentration (MBC) of all the peptides were twice the MIC. CAMA‐CPP and CAMA were found to be stable under different conditions (high‐end temperatures, proteinase‐K, cationic salts, pH and serum) when compared to the other CPPs. Moreover, CAMA‐CPP exhibited negligible cytotoxicity in HEp‐2 and RAW 264.7 cell lines as well as haemolysis in the sheep and human erythrocytes with no adverse effects against the commensal gut lactobacilli. In vitro time‐kill assay revealed that the MBC levels of CAMA‐CPP and APP could eliminate the intracellular MDR‐Salmonella infections from mammalian cell lines; however, CAMA and P7 peptides were ineffective. CAMA‐CPP appears to be a promising antimicrobial candidate and opens up further avenues for its in vivo clinical translation.

show abstract

Exploiting Lactoferricin (17–30) as a Potential Antimicrobial and Antibiofilm Candidate Against Multi-Drug-Resistant Enteroaggregative Escherichia coli

Cited by 9 publications

References 76 publications

Antimicrobial peptide Mastoparan X has good activity against Escherichia coli in vitro and alleviates its pathogenicity in mice

Antimicrobial peptide Mastoparan X has good activity against Escherichia coli in vitro and alleviates its pathogenicity in mice

The Mechanism of Antimicrobial Peptide MPX against Enterohemorrhagic Escherichia coli in Vitro

Antibacterial efficacy of in‐house designed cell‐penetrating peptide against multi‐drug resistant strains of Salmonella Enteritidis and Salmonella Typhimurium

Contact Info

Product

Resources

About